Why Now Daily.

Published

PSA Screening: Benefits, Limits and Follow-Up

Prostate-specific antigen is made by normal and malignant prostate cells, so a blood level can rise with cancer, benign enlargement, inflammation, infection and recent prostate irritation. PSA screening may find clinically important cancer earlier, but it can also produce false positives, biopsies, overdiagnosis and…

Timeline

  1. 2023-09-05: The AUA/SUO published its unabridged guideline on early detection of prostate cancer.
  2. 2026-10-12: The USPSTF screening recommendation remained under update; current NCI, MedlinePlus and AUA guidance was reviewed.

Prostate-specific antigen, or PSA, is a protein made by prostate cells, including normal cells and cancer cells. A PSA test measures its concentration in blood. It is used in different settings: screening people without symptoms, investigating prostate-related symptoms and monitoring known prostate cancer after diagnosis or treatment. Those uses should not be mixed. A value that prompts a screening discussion is interpreted differently from a post-treatment value, where a person’s established diagnosis and prior trend guide the question. [1][2]

PSA is prostate-specific but not cancer-specific. Benign prostate enlargement, prostatitis, urinary infection, recent biopsy or urinary instrumentation, ejaculation and some vigorous activities can raise it temporarily. Medicines used for benign enlargement, including drugs that reduce prostate size, may lower PSA and change interpretation. Tell the clinician about symptoms, procedures, medicines and supplements, and follow preparation instructions. Do not stop a prescription or take antibiotics simply to alter the number without medical advice. [1][2]

There is no single concentration that cleanly divides cancer from no cancer. Cancer can occur with a relatively low PSA, while many people with an elevated PSA do not have cancer. Risk generally rises as the level rises, but age, prostate size, family history, prior results and examination matter. This is why an isolated portal flag is not a diagnosis and why “normal for age” is not an absolute guarantee. The trend can add context, but the speed of change should not be used alone to trigger biopsy. [1][2][4]

Screening has a real tradeoff. It may identify an aggressive cancer before symptoms or spread, offering some people an opportunity for earlier treatment. It also produces false positives, anxiety and additional testing. Screening can detect slow-growing cancers that would never have caused illness during a person’s life; treatment of those overdiagnosed cancers can cause urinary, sexual and bowel harms. The balance depends on life expectancy, competing health risks, baseline cancer risk and how the person values those possible outcomes. [1][3][4]

Guidelines differ, so age bands are not universal instructions. The 2023 AUA/SUO guideline calls PSA screening preference-sensitive and recommends shared decision-making for people in whom screening is appropriate. The existing 2018 USPSTF recommendation says U.S. men aged 55 to 69 should make an individual decision after discussing benefits and harms and recommends against routine PSA screening at 70 or older; the USPSTF page states that this topic is being updated. Family history, Black ancestry, certain inherited variants and overall health can change when a discussion begins. [3][4]

An unexpected elevation usually starts a process, not an immediate biopsy. NCI and AUA guidance support repeating a newly elevated PSA before moving to a secondary biomarker, imaging or biopsy, because levels fluctuate and reversible causes may be present. If concern persists, clinicians may consider percent-free PSA or other validated blood or urine tools, a digital rectal examination and multiparametric MRI. These tools estimate the chance of clinically significant cancer and help decide whether and where to biopsy; none independently provides a tissue diagnosis. [1][2][4]

A prostate biopsy is the procedure that can establish cancer by showing malignant cells in tissue. Biopsy can cause bleeding, infection, pain or urinary difficulty, and it can still miss a lesion, so the decision weighs predicted risk against harms. If cancer is found, grade, extent, imaging, age and health guide whether active surveillance or treatment is appropriate. Finding cancer does not automatically mean immediate surgery or radiation, just as a high PSA does not automatically mean cancer. [1][2][3]

Before choosing screening, ask what benefit is plausible for your health and risk profile, what interval and stopping plan the clinician proposes, and what would happen after an abnormal result. Before interpreting a result, confirm whether it was a screening, symptom-evaluation or monitoring test and whether infection, ejaculation, cycling, a procedure or medication could affect it. New urinary retention, fever with urinary symptoms, blood in urine or severe pain needs clinical assessment regardless of PSA. The useful decision is a shared plan for testing and follow-up, not pursuit of one universal target number. [1][2][3][4]

Sources

  1. National Cancer Institute — Prostate-Specific Antigen (PSA) Test
  2. MedlinePlus — Prostate-Specific Antigen (PSA) Test
  3. U.S. Preventive Services Task Force — Prostate Cancer: Screening
  4. American Urological Association — Early Detection of Prostate Cancer: AUA/SUO Guideline (2023)

Related stories